Hongling Peng

机构：Central South University, Sichuan University, West China Second University Hospital of Sichuan University, Second Xiangya Hospital of Central South University, Education Department of Hunan Province · ORCID：0000-0003-2770-5150

发表论文 214 篇 · 总被引 2939 次 · h-index 29

代表论文

• Prospective phase II trial of first-line rituximab, methotrexate, and orelabrutinib (R-MO) in primary central nervous system lymphoma (2025 · Blood Cancer Journal · 被引 8)
• Clinical characteristics and survival outcomes of thymic mucosa‐associated lymphoid tissue lymphoma: A multicenter analysis of 82 patients (2025 · Cancer · 被引 2)
• Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study (2026 · Annals of Hematology · 被引 1)
• HLTF cooperates with GATA1 to activate transcriptional programs and chromatin remodeling during erythroid development (2026 · Nucleic Acids Research · 被引 1)
• Venetoclax combined with homoharringtonine, cytarabine and aclacinomycin as induction therapy in newly diagnosed Chinese acute myeloid leukaemia patients: A multicentre phase II study (2025 · British Journal of Haematology · 被引 1)
• Single cell sequencing deciphering the heterogeneous landscape of blastic plasmacytoid dendritic cell neoplasm with novel MYB-ZFAT fusion gene (2025 · Cancer Cell International · 被引 1)